2017

Backed

by HTGF since
Exit

KSK Diagnostics

Invested since 2017
Based in Hamburg

About the company

KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the time before therapy is started. In addition to the diagnosis of pathogens, KSK Diagnostics’ point-of-care tests are ideally suited to quickly and reliably clarifying issues related to tumour diagnostics.

Do you want to

know more about this company?

Zum Artikel

Dr. Frank Hensel Principal

Dr. Frank HenselPrincipal

More startups from Life Sciences